Shortage of Execution Drugs Becomes More AcuteDeborah Denno in ABC News, February 19, 2014
Shortage of Execution Drugs Becomes More Acute
By JIM SALTER
The nation's shortage of execution drugs is becoming increasingly acute as more pharmacies conclude that supplying the lethal chemicals is not worth the bad publicity and the legal and ethical risks.
The scarcity of drugs for lethal injections has forced states to scramble for substitutes. And experts say that whatever alternatives are found will almost certainly face costly court challenges made more complicated by laws that cloak the process in secrecy.
On Monday, the Tulsa, Okla.-based compounding pharmacy the Apothecary Shoppe agreed to stop selling pentobarbital to the Missouri Department of Corrections after the pharmacy was named in a lawsuit filed by death row inmate Michael Taylor alleging that the drug could cause "inhumane pain."
Missouri previously paid $8,000 in cash for each dose of the drug. The settlement will probably mean changing delicate execution procedures just a week before Taylor is scheduled to die for raping and killing a 15-year-old Kansas City girl in 1989. Gov. Jay Nixon said Tuesday that Missouri is prepared to carry out the Feb. 26 execution but declined to elaborate.
Messages left with spokesmen for the corrections department were not returned. The Apothecary Shoppe declined interview requests or to answer emailed questions.
Missouri, like many states, is reluctant to divulge much information about how, or where, it obtains lethal injection drugs, citing the privacy rights of the supplier.
Lethal injection has faced increasing scrutiny over the past decade. Major drug makers, many of them based in Europe with longtime opposition to the death penalty, have stopped selling to prisons and corrections departments. The source of the drugs is moving to the forefront of the death penalty debate.
Compounding pharmacies — which custom-mix prescription drugs for doctors and patients — seemed like the answer. They are generally overseen by state boards, not the U.S. Food and Drug Administration, although a law adopted last year allows larger compounding pharmacies to register with the FDA and submit to federal inspections.
But now, some compounding pharmacies are starting to back away, too.
Experts say they're not surprised, given the limited profit in selling execution drugs, ethical concerns in the medical profession, potential legal costs and unwanted publicity.
"This is not a good business model for compounding pharmacies, to be making drugs for executions, particularly with all the secret ways they're doing it," Fordam Law School professor Deborah Denno said.
Richard Dieter, executive director of the Washington-based Death Penalty Information Center, agreed.
"I'm sure they've never had such publicity," Dieter said. "They must be wondering what they got themselves into."
In Texas, the nation's most active death-penalty state, where 510 lethal injections have been carried out since 1982, the supply of pentobarbital may be running low.
After Woodlands Compounding Pharmacy near Houston was revealed in October as the supplier for Texas, the pharmacy asked the state Department of Criminal Justice to return unused vials. The state refused to do so.
The state's existing supply expires April 1. Texas has two executions scheduled for March and five others after the expiration date.